On November 12, as of the close of the Hong Kong stock market, the Hang Seng Index fell 2.84%to 19846.88 points.The Bio Olympic-B (02315.HK) closed at HK $ 5.99/share, down 1.16%, the transaction volume was 219,500 shares, and the turnover was HK $ 1.323 million, with an amplitude of 4.62%.
In the past month, the cumulative decline of Bisai-B-B-B. This year, a total of 49.42%, and 19.82%of the Hang Seng Index.
Financial data shows that as of June 30, 2024, the total operating income of the Bisai-B-B-B of the Biso-B increased by 25.6%year-on-year; the net profit of home mother-50.673 million yuan, Year -on -year increased by 73.3%; gross profit margin was 74.42%, and the asset -liability ratio was 69.4%.
In terms of institutional rating, there is currently no proposal to invest investment rating for the stock.
In terms of industry valuation, the average price-earnings ratio of the drug and biotechnology industry (TTM) is 5.49 times, and the industry medium value is -0.48 times.Bio Olympic-B P / E ratio -8.89 times, the industry ranks 101st; other Baixin International (00574.HK) is 1.74 times, Dongrui Pharmaceutical (02348.HK) is 3.02 times, Liankang Biotechnology Group (00690.HK) It is 3.99 times, Jilin Changlong Pharmaceutical (08049.HK) is 4.18 times, Yangtze River Pharmaceutical (01558.HK) is 4.28 times.
According to the data, Baina Chaotu (Beijing) Pharmaceutical Technology Co., Ltd. is an international biotechnology company developed by innovative technology to drive new drugs.Technological innovation, continuous new drug output, and guarding human health.Based on the independent developed and independent intellectual property rights, the Renmicetm platform (Renmab and Renlite mice), which has completely independent intellectual property rights, organically integrate monoclonal and dual -anti -development technology platforms, animal body effect screening platforms, and strong clinical development capabilities.Together, a new drug research and development capabilities covering the entire process of drug research and development have been formed.Bio Au is developing a large -scale drug development of more than 1,000 potential patent medicine targets (the "" Thousands of Rats and TM "Plan). With the implementation of the plan, Bisai Tume has signed 24 drug cooperation development agreements and and with with.14 companies, including multiple MNCs, have reached the Renmice platform authorization cooperation.The company has now established 12 core drug product pipelines, of which 2 products are phase II in the International Multi -Center (MRCT) clinical trials and two in the clinical trial stage I.In the future, Bio Orgu will continue to work with global partners to continue to produce many antibody drugs to better benefit patients.The headquarters of the Bao Olympic Tu is located in Beijing, with branches in Haimen in Jiangsu, Shanghai and Boston, USA.
(The above content is a public message based on the financial industry, which is intelligently generated by the program or algorithm.This article comes from: the financial industry
Author: Quotation Jun
